ZyVersa Therapeutics (NASDAQ:ZVSA) Trading Up 7.5%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) rose 7.5% on Thursday . The stock traded as high as $0.64 and last traded at $0.63. Approximately 422,022 shares changed hands during trading, a decline of 82% from the average daily volume of 2,335,399 shares. The stock had previously closed at $0.58.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of ZyVersa Therapeutics in a research report on Tuesday, March 26th.

ZyVersa Therapeutics Stock Down 6.4 %

The firm has a fifty day simple moving average of $0.76 and a 200 day simple moving average of $1.63.

Hedge Funds Weigh In On ZyVersa Therapeutics

An institutional investor recently bought a new position in ZyVersa Therapeutics stock. Walleye Capital LLC purchased a new stake in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 980,568 shares of the company’s stock, valued at approximately $128,000. Walleye Capital LLC owned approximately 3.17% of ZyVersa Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 3.91% of the company’s stock.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases.